nodes	percent_of_prediction	percent_of_DWPC	metapath
Vardenafil—PDE5A—clitoris—urinary bladder cancer	0.155	0.399	CbGeAlD
Vardenafil—PDE5A—penis—urinary bladder cancer	0.044	0.113	CbGeAlD
Vardenafil—PDE11A—prostate gland—urinary bladder cancer	0.0276	0.0709	CbGeAlD
Vardenafil—PDE11A—epithelium—urinary bladder cancer	0.0203	0.0521	CbGeAlD
Vardenafil—PDE10A—prostate gland—urinary bladder cancer	0.018	0.0461	CbGeAlD
Vardenafil—PDE1B—prostate gland—urinary bladder cancer	0.0178	0.0457	CbGeAlD
Vardenafil—PDE5A—prostate gland—urinary bladder cancer	0.0105	0.027	CbGeAlD
Vardenafil—PDE1B—female reproductive system—urinary bladder cancer	0.00971	0.025	CbGeAlD
Vardenafil—CYP3A4—urine—urinary bladder cancer	0.00912	0.0234	CbGeAlD
Vardenafil—PDE6G—lymph node—urinary bladder cancer	0.00849	0.0218	CbGeAlD
Vardenafil—PDE5A—epithelium—urinary bladder cancer	0.00772	0.0198	CbGeAlD
Vardenafil—PDE5A—smooth muscle tissue—urinary bladder cancer	0.00744	0.0191	CbGeAlD
Vardenafil—PDE5A—renal system—urinary bladder cancer	0.00716	0.0184	CbGeAlD
Vardenafil—PDE5A—urethra—urinary bladder cancer	0.00703	0.0181	CbGeAlD
Vardenafil—PDE5A—female reproductive system—urinary bladder cancer	0.00573	0.0147	CbGeAlD
Vardenafil—PDE10A—lymph node—urinary bladder cancer	0.00573	0.0147	CbGeAlD
Vardenafil—PDE1B—lymph node—urinary bladder cancer	0.00568	0.0146	CbGeAlD
Vardenafil—PDE5A—vagina—urinary bladder cancer	0.00519	0.0133	CbGeAlD
Vardenafil—CYP3A5—prostate gland—urinary bladder cancer	0.00436	0.0112	CbGeAlD
Vardenafil—PDE5A—lymph node—urinary bladder cancer	0.00335	0.00862	CbGeAlD
Vardenafil—CYP3A5—renal system—urinary bladder cancer	0.00297	0.00764	CbGeAlD
Vardenafil—CYP3A4—renal system—urinary bladder cancer	0.00223	0.00573	CbGeAlD
Vardenafil—CYP3A5—vagina—urinary bladder cancer	0.00215	0.00554	CbGeAlD
Vardenafil—CYP3A4—female reproductive system—urinary bladder cancer	0.00179	0.00459	CbGeAlD
Vardenafil—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000585	0.00113	CcSEcCtD
Vardenafil—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000585	0.00113	CcSEcCtD
Vardenafil—Paraesthesia—Etoposide—urinary bladder cancer	0.000584	0.00113	CcSEcCtD
Vardenafil—Haematuria—Methotrexate—urinary bladder cancer	0.000582	0.00113	CcSEcCtD
Vardenafil—Dyspnoea—Etoposide—urinary bladder cancer	0.000579	0.00112	CcSEcCtD
Vardenafil—Somnolence—Etoposide—urinary bladder cancer	0.000578	0.00112	CcSEcCtD
Vardenafil—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000577	0.00112	CcSEcCtD
Vardenafil—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000577	0.00112	CcSEcCtD
Vardenafil—Epistaxis—Methotrexate—urinary bladder cancer	0.000576	0.00111	CcSEcCtD
Vardenafil—Vomiting—Thiotepa—urinary bladder cancer	0.000575	0.00111	CcSEcCtD
Vardenafil—Infestation—Epirubicin—urinary bladder cancer	0.000571	0.00111	CcSEcCtD
Vardenafil—Infestation NOS—Epirubicin—urinary bladder cancer	0.000571	0.00111	CcSEcCtD
Vardenafil—Rash—Thiotepa—urinary bladder cancer	0.000571	0.0011	CcSEcCtD
Vardenafil—Dermatitis—Thiotepa—urinary bladder cancer	0.00057	0.0011	CcSEcCtD
Vardenafil—Headache—Thiotepa—urinary bladder cancer	0.000567	0.0011	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000561	0.00109	CcSEcCtD
Vardenafil—Pain—Etoposide—urinary bladder cancer	0.000556	0.00108	CcSEcCtD
Vardenafil—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000555	0.00107	CcSEcCtD
Vardenafil—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000551	0.00107	CcSEcCtD
Vardenafil—Haemoglobin—Methotrexate—urinary bladder cancer	0.000551	0.00107	CcSEcCtD
Vardenafil—Haemorrhage—Methotrexate—urinary bladder cancer	0.000548	0.00106	CcSEcCtD
Vardenafil—Sweating—Epirubicin—urinary bladder cancer	0.000548	0.00106	CcSEcCtD
Vardenafil—Asthenia—Gemcitabine—urinary bladder cancer	0.000546	0.00106	CcSEcCtD
Vardenafil—Haematuria—Epirubicin—urinary bladder cancer	0.000545	0.00105	CcSEcCtD
Vardenafil—Pharyngitis—Methotrexate—urinary bladder cancer	0.000544	0.00105	CcSEcCtD
Vardenafil—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000541	0.00105	CcSEcCtD
Vardenafil—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000541	0.00105	CcSEcCtD
Vardenafil—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00054	0.00105	CcSEcCtD
Vardenafil—Epistaxis—Epirubicin—urinary bladder cancer	0.000539	0.00104	CcSEcCtD
Vardenafil—Pruritus—Gemcitabine—urinary bladder cancer	0.000539	0.00104	CcSEcCtD
Vardenafil—Nausea—Thiotepa—urinary bladder cancer	0.000537	0.00104	CcSEcCtD
Vardenafil—Urethral disorder—Methotrexate—urinary bladder cancer	0.000537	0.00104	CcSEcCtD
Vardenafil—Sinusitis—Epirubicin—urinary bladder cancer	0.000536	0.00104	CcSEcCtD
Vardenafil—Feeling abnormal—Etoposide—urinary bladder cancer	0.000536	0.00104	CcSEcCtD
Vardenafil—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000532	0.00103	CcSEcCtD
Vardenafil—Pruritus—Fluorouracil—urinary bladder cancer	0.00053	0.00102	CcSEcCtD
Vardenafil—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000529	0.00102	CcSEcCtD
Vardenafil—Infestation—Doxorubicin—urinary bladder cancer	0.000529	0.00102	CcSEcCtD
Vardenafil—Visual impairment—Methotrexate—urinary bladder cancer	0.000528	0.00102	CcSEcCtD
Vardenafil—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000523	0.00101	CcSEcCtD
Vardenafil—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000521	0.00101	CcSEcCtD
Vardenafil—Haemoglobin—Epirubicin—urinary bladder cancer	0.000515	0.000997	CcSEcCtD
Vardenafil—Rhinitis—Epirubicin—urinary bladder cancer	0.000514	0.000995	CcSEcCtD
Vardenafil—Abdominal pain—Etoposide—urinary bladder cancer	0.000514	0.000994	CcSEcCtD
Vardenafil—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000514	0.000994	CcSEcCtD
Vardenafil—Haemorrhage—Epirubicin—urinary bladder cancer	0.000513	0.000992	CcSEcCtD
Vardenafil—Eye disorder—Methotrexate—urinary bladder cancer	0.000512	0.000991	CcSEcCtD
Vardenafil—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000512	0.000991	CcSEcCtD
Vardenafil—Tinnitus—Methotrexate—urinary bladder cancer	0.000511	0.000989	CcSEcCtD
Vardenafil—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.00051	0.000987	CcSEcCtD
Vardenafil—Asthenia—Cisplatin—urinary bladder cancer	0.000509	0.000985	CcSEcCtD
Vardenafil—Pharyngitis—Epirubicin—urinary bladder cancer	0.000509	0.000985	CcSEcCtD
Vardenafil—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000509	0.000984	CcSEcCtD
Vardenafil—Sweating—Doxorubicin—urinary bladder cancer	0.000507	0.000981	CcSEcCtD
Vardenafil—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000506	0.00098	CcSEcCtD
Vardenafil—Haematuria—Doxorubicin—urinary bladder cancer	0.000504	0.000975	CcSEcCtD
Vardenafil—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000504	0.000975	CcSEcCtD
Vardenafil—Urethral disorder—Epirubicin—urinary bladder cancer	0.000503	0.000973	CcSEcCtD
Vardenafil—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.0005	0.000967	CcSEcCtD
Vardenafil—Epistaxis—Doxorubicin—urinary bladder cancer	0.000499	0.000965	CcSEcCtD
Vardenafil—Angiopathy—Methotrexate—urinary bladder cancer	0.000497	0.000962	CcSEcCtD
Vardenafil—Sinusitis—Doxorubicin—urinary bladder cancer	0.000496	0.00096	CcSEcCtD
Vardenafil—Immune system disorder—Methotrexate—urinary bladder cancer	0.000495	0.000958	CcSEcCtD
Vardenafil—Dizziness—Fluorouracil—urinary bladder cancer	0.000495	0.000958	CcSEcCtD
Vardenafil—Visual impairment—Epirubicin—urinary bladder cancer	0.000494	0.000956	CcSEcCtD
Vardenafil—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000494	0.000956	CcSEcCtD
Vardenafil—Diarrhoea—Cisplatin—urinary bladder cancer	0.000485	0.000939	CcSEcCtD
Vardenafil—Vomiting—Gemcitabine—urinary bladder cancer	0.000484	0.000936	CcSEcCtD
Vardenafil—Mental disorder—Methotrexate—urinary bladder cancer	0.00048	0.000929	CcSEcCtD
Vardenafil—Rash—Gemcitabine—urinary bladder cancer	0.00048	0.000929	CcSEcCtD
Vardenafil—Dermatitis—Gemcitabine—urinary bladder cancer	0.00048	0.000928	CcSEcCtD
Vardenafil—Eye disorder—Epirubicin—urinary bladder cancer	0.000479	0.000927	CcSEcCtD
Vardenafil—Hypersensitivity—Etoposide—urinary bladder cancer	0.000479	0.000927	CcSEcCtD
Vardenafil—Tinnitus—Epirubicin—urinary bladder cancer	0.000478	0.000925	CcSEcCtD
Vardenafil—Erythema—Methotrexate—urinary bladder cancer	0.000477	0.000923	CcSEcCtD
Vardenafil—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000477	0.000923	CcSEcCtD
Vardenafil—Headache—Gemcitabine—urinary bladder cancer	0.000477	0.000923	CcSEcCtD
Vardenafil—Flushing—Epirubicin—urinary bladder cancer	0.000476	0.000921	CcSEcCtD
Vardenafil—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000476	0.000921	CcSEcCtD
Vardenafil—Vomiting—Fluorouracil—urinary bladder cancer	0.000476	0.000921	CcSEcCtD
Vardenafil—Rhinitis—Doxorubicin—urinary bladder cancer	0.000476	0.000921	CcSEcCtD
Vardenafil—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000475	0.000918	CcSEcCtD
Vardenafil—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000472	0.000914	CcSEcCtD
Vardenafil—Rash—Fluorouracil—urinary bladder cancer	0.000472	0.000913	CcSEcCtD
Vardenafil—Dermatitis—Fluorouracil—urinary bladder cancer	0.000471	0.000912	CcSEcCtD
Vardenafil—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000471	0.000911	CcSEcCtD
Vardenafil—Headache—Fluorouracil—urinary bladder cancer	0.000469	0.000907	CcSEcCtD
Vardenafil—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000469	0.000907	CcSEcCtD
Vardenafil—Asthenia—Etoposide—urinary bladder cancer	0.000466	0.000902	CcSEcCtD
Vardenafil—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000466	0.000902	CcSEcCtD
Vardenafil—Angiopathy—Epirubicin—urinary bladder cancer	0.000465	0.0009	CcSEcCtD
Vardenafil—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000465	0.0009	CcSEcCtD
Vardenafil—Immune system disorder—Epirubicin—urinary bladder cancer	0.000463	0.000896	CcSEcCtD
Vardenafil—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000462	0.000894	CcSEcCtD
Vardenafil—Back pain—Methotrexate—urinary bladder cancer	0.000461	0.000893	CcSEcCtD
Vardenafil—Pruritus—Etoposide—urinary bladder cancer	0.00046	0.00089	CcSEcCtD
Vardenafil—Visual impairment—Doxorubicin—urinary bladder cancer	0.000457	0.000885	CcSEcCtD
Vardenafil—Nausea—Gemcitabine—urinary bladder cancer	0.000452	0.000875	CcSEcCtD
Vardenafil—Vomiting—Cisplatin—urinary bladder cancer	0.000451	0.000873	CcSEcCtD
Vardenafil—Vision blurred—Methotrexate—urinary bladder cancer	0.00045	0.00087	CcSEcCtD
Vardenafil—Mental disorder—Epirubicin—urinary bladder cancer	0.000449	0.000869	CcSEcCtD
Vardenafil—Rash—Cisplatin—urinary bladder cancer	0.000447	0.000866	CcSEcCtD
Vardenafil—Dermatitis—Cisplatin—urinary bladder cancer	0.000447	0.000865	CcSEcCtD
Vardenafil—Erythema—Epirubicin—urinary bladder cancer	0.000446	0.000864	CcSEcCtD
Vardenafil—Diarrhoea—Etoposide—urinary bladder cancer	0.000445	0.000861	CcSEcCtD
Vardenafil—Nausea—Fluorouracil—urinary bladder cancer	0.000445	0.00086	CcSEcCtD
Vardenafil—Eye disorder—Doxorubicin—urinary bladder cancer	0.000443	0.000858	CcSEcCtD
Vardenafil—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000443	0.000856	CcSEcCtD
Vardenafil—Tinnitus—Doxorubicin—urinary bladder cancer	0.000442	0.000856	CcSEcCtD
Vardenafil—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00044	0.000852	CcSEcCtD
Vardenafil—Flushing—Doxorubicin—urinary bladder cancer	0.00044	0.000852	CcSEcCtD
Vardenafil—Back pain—Epirubicin—urinary bladder cancer	0.000432	0.000836	CcSEcCtD
Vardenafil—Angiopathy—Doxorubicin—urinary bladder cancer	0.000431	0.000833	CcSEcCtD
Vardenafil—Malaise—Methotrexate—urinary bladder cancer	0.00043	0.000832	CcSEcCtD
Vardenafil—Dizziness—Etoposide—urinary bladder cancer	0.00043	0.000832	CcSEcCtD
Vardenafil—Muscle spasms—Epirubicin—urinary bladder cancer	0.000429	0.000831	CcSEcCtD
Vardenafil—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000429	0.000829	CcSEcCtD
Vardenafil—Vertigo—Methotrexate—urinary bladder cancer	0.000429	0.000829	CcSEcCtD
Vardenafil—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000428	0.000828	CcSEcCtD
Vardenafil—Nausea—Cisplatin—urinary bladder cancer	0.000421	0.000815	CcSEcCtD
Vardenafil—Vision blurred—Epirubicin—urinary bladder cancer	0.000421	0.000814	CcSEcCtD
Vardenafil—Mental disorder—Doxorubicin—urinary bladder cancer	0.000416	0.000804	CcSEcCtD
Vardenafil—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000414	0.000802	CcSEcCtD
Vardenafil—Convulsion—Methotrexate—urinary bladder cancer	0.000413	0.0008	CcSEcCtD
Vardenafil—Vomiting—Etoposide—urinary bladder cancer	0.000413	0.0008	CcSEcCtD
Vardenafil—Erythema—Doxorubicin—urinary bladder cancer	0.000413	0.000799	CcSEcCtD
Vardenafil—Rash—Etoposide—urinary bladder cancer	0.00041	0.000793	CcSEcCtD
Vardenafil—Dermatitis—Etoposide—urinary bladder cancer	0.000409	0.000792	CcSEcCtD
Vardenafil—Headache—Etoposide—urinary bladder cancer	0.000407	0.000788	CcSEcCtD
Vardenafil—Arthralgia—Methotrexate—urinary bladder cancer	0.000406	0.000786	CcSEcCtD
Vardenafil—Chest pain—Methotrexate—urinary bladder cancer	0.000406	0.000786	CcSEcCtD
Vardenafil—Myalgia—Methotrexate—urinary bladder cancer	0.000406	0.000786	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000403	0.00078	CcSEcCtD
Vardenafil—Malaise—Epirubicin—urinary bladder cancer	0.000403	0.000779	CcSEcCtD
Vardenafil—Discomfort—Methotrexate—urinary bladder cancer	0.000401	0.000776	CcSEcCtD
Vardenafil—Vertigo—Epirubicin—urinary bladder cancer	0.000401	0.000776	CcSEcCtD
Vardenafil—Syncope—Epirubicin—urinary bladder cancer	0.0004	0.000775	CcSEcCtD
Vardenafil—Back pain—Doxorubicin—urinary bladder cancer	0.0004	0.000773	CcSEcCtD
Vardenafil—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000397	0.000768	CcSEcCtD
Vardenafil—Palpitations—Epirubicin—urinary bladder cancer	0.000395	0.000763	CcSEcCtD
Vardenafil—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000392	0.000759	CcSEcCtD
Vardenafil—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000389	0.000753	CcSEcCtD
Vardenafil—Vision blurred—Doxorubicin—urinary bladder cancer	0.000389	0.000753	CcSEcCtD
Vardenafil—Convulsion—Epirubicin—urinary bladder cancer	0.000387	0.000748	CcSEcCtD
Vardenafil—Infection—Methotrexate—urinary bladder cancer	0.000387	0.000748	CcSEcCtD
Vardenafil—Nausea—Etoposide—urinary bladder cancer	0.000386	0.000747	CcSEcCtD
Vardenafil—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000383	0.000742	CcSEcCtD
Vardenafil—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000382	0.000739	CcSEcCtD
Vardenafil—Arthralgia—Epirubicin—urinary bladder cancer	0.00038	0.000735	CcSEcCtD
Vardenafil—Chest pain—Epirubicin—urinary bladder cancer	0.00038	0.000735	CcSEcCtD
Vardenafil—Myalgia—Epirubicin—urinary bladder cancer	0.00038	0.000735	CcSEcCtD
Vardenafil—Anxiety—Epirubicin—urinary bladder cancer	0.000379	0.000733	CcSEcCtD
Vardenafil—Skin disorder—Methotrexate—urinary bladder cancer	0.000378	0.000732	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000377	0.00073	CcSEcCtD
Vardenafil—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000376	0.000728	CcSEcCtD
Vardenafil—Discomfort—Epirubicin—urinary bladder cancer	0.000376	0.000727	CcSEcCtD
Vardenafil—Malaise—Doxorubicin—urinary bladder cancer	0.000373	0.000721	CcSEcCtD
Vardenafil—Dry mouth—Epirubicin—urinary bladder cancer	0.000372	0.000719	CcSEcCtD
Vardenafil—Vertigo—Doxorubicin—urinary bladder cancer	0.000371	0.000718	CcSEcCtD
Vardenafil—Syncope—Doxorubicin—urinary bladder cancer	0.00037	0.000717	CcSEcCtD
Vardenafil—Palpitations—Doxorubicin—urinary bladder cancer	0.000365	0.000706	CcSEcCtD
Vardenafil—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000364	0.000705	CcSEcCtD
Vardenafil—Hypotension—Methotrexate—urinary bladder cancer	0.000364	0.000704	CcSEcCtD
Vardenafil—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000363	0.000703	CcSEcCtD
Vardenafil—Infection—Epirubicin—urinary bladder cancer	0.000362	0.0007	CcSEcCtD
Vardenafil—Shock—Epirubicin—urinary bladder cancer	0.000358	0.000694	CcSEcCtD
Vardenafil—Convulsion—Doxorubicin—urinary bladder cancer	0.000358	0.000693	CcSEcCtD
Vardenafil—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000357	0.000691	CcSEcCtD
Vardenafil—Tachycardia—Epirubicin—urinary bladder cancer	0.000356	0.000688	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000355	0.000686	CcSEcCtD
Vardenafil—Skin disorder—Epirubicin—urinary bladder cancer	0.000354	0.000685	CcSEcCtD
Vardenafil—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000352	0.000682	CcSEcCtD
Vardenafil—Insomnia—Methotrexate—urinary bladder cancer	0.000352	0.000681	CcSEcCtD
Vardenafil—Myalgia—Doxorubicin—urinary bladder cancer	0.000352	0.00068	CcSEcCtD
Vardenafil—Arthralgia—Doxorubicin—urinary bladder cancer	0.000352	0.00068	CcSEcCtD
Vardenafil—Chest pain—Doxorubicin—urinary bladder cancer	0.000352	0.00068	CcSEcCtD
Vardenafil—Anxiety—Doxorubicin—urinary bladder cancer	0.00035	0.000678	CcSEcCtD
Vardenafil—Paraesthesia—Methotrexate—urinary bladder cancer	0.00035	0.000676	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000349	0.000676	CcSEcCtD
Vardenafil—Discomfort—Doxorubicin—urinary bladder cancer	0.000347	0.000672	CcSEcCtD
Vardenafil—Dyspnoea—Methotrexate—urinary bladder cancer	0.000347	0.000672	CcSEcCtD
Vardenafil—Somnolence—Methotrexate—urinary bladder cancer	0.000346	0.00067	CcSEcCtD
Vardenafil—Dry mouth—Doxorubicin—urinary bladder cancer	0.000344	0.000666	CcSEcCtD
Vardenafil—Dyspepsia—Methotrexate—urinary bladder cancer	0.000343	0.000663	CcSEcCtD
Vardenafil—Hypotension—Epirubicin—urinary bladder cancer	0.00034	0.000659	CcSEcCtD
Vardenafil—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000337	0.000652	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000336	0.00065	CcSEcCtD
Vardenafil—Infection—Doxorubicin—urinary bladder cancer	0.000335	0.000648	CcSEcCtD
Vardenafil—Pain—Methotrexate—urinary bladder cancer	0.000333	0.000644	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000332	0.000642	CcSEcCtD
Vardenafil—Shock—Doxorubicin—urinary bladder cancer	0.000332	0.000642	CcSEcCtD
Vardenafil—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000331	0.00064	CcSEcCtD
Vardenafil—Insomnia—Epirubicin—urinary bladder cancer	0.00033	0.000638	CcSEcCtD
Vardenafil—Tachycardia—Doxorubicin—urinary bladder cancer	0.000329	0.000637	CcSEcCtD
Vardenafil—Skin disorder—Doxorubicin—urinary bladder cancer	0.000327	0.000634	CcSEcCtD
Vardenafil—Paraesthesia—Epirubicin—urinary bladder cancer	0.000327	0.000633	CcSEcCtD
Vardenafil—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000326	0.000631	CcSEcCtD
Vardenafil—Dyspnoea—Epirubicin—urinary bladder cancer	0.000325	0.000629	CcSEcCtD
Vardenafil—Somnolence—Epirubicin—urinary bladder cancer	0.000324	0.000627	CcSEcCtD
Vardenafil—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000321	0.000621	CcSEcCtD
Vardenafil—Dyspepsia—Epirubicin—urinary bladder cancer	0.000321	0.000621	CcSEcCtD
Vardenafil—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000318	0.000616	CcSEcCtD
Vardenafil—Hypotension—Doxorubicin—urinary bladder cancer	0.000315	0.00061	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000315	0.000609	CcSEcCtD
Vardenafil—Pain—Epirubicin—urinary bladder cancer	0.000312	0.000603	CcSEcCtD
Vardenafil—Abdominal pain—Methotrexate—urinary bladder cancer	0.000308	0.000596	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000307	0.000594	CcSEcCtD
Vardenafil—Insomnia—Doxorubicin—urinary bladder cancer	0.000305	0.00059	CcSEcCtD
Vardenafil—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000303	0.000586	CcSEcCtD
Vardenafil—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000301	0.000582	CcSEcCtD
Vardenafil—Feeling abnormal—Epirubicin—urinary bladder cancer	0.0003	0.000581	CcSEcCtD
Vardenafil—Somnolence—Doxorubicin—urinary bladder cancer	0.0003	0.00058	CcSEcCtD
Vardenafil—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000298	0.000577	CcSEcCtD
Vardenafil—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000297	0.000574	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000291	0.000563	CcSEcCtD
Vardenafil—Pain—Doxorubicin—urinary bladder cancer	0.000288	0.000558	CcSEcCtD
Vardenafil—Abdominal pain—Epirubicin—urinary bladder cancer	0.000288	0.000557	CcSEcCtD
Vardenafil—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000287	0.000555	CcSEcCtD
Vardenafil—Asthenia—Methotrexate—urinary bladder cancer	0.000279	0.000541	CcSEcCtD
Vardenafil—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000278	0.000538	CcSEcCtD
Vardenafil—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000276	0.000533	CcSEcCtD
Vardenafil—Pruritus—Methotrexate—urinary bladder cancer	0.000275	0.000533	CcSEcCtD
Vardenafil—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000268	0.000519	CcSEcCtD
Vardenafil—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000267	0.000516	CcSEcCtD
Vardenafil—Diarrhoea—Methotrexate—urinary bladder cancer	0.000266	0.000515	CcSEcCtD
Vardenafil—Asthenia—Epirubicin—urinary bladder cancer	0.000261	0.000506	CcSEcCtD
Vardenafil—Pruritus—Epirubicin—urinary bladder cancer	0.000258	0.000499	CcSEcCtD
Vardenafil—Dizziness—Methotrexate—urinary bladder cancer	0.000257	0.000498	CcSEcCtD
Vardenafil—Diarrhoea—Epirubicin—urinary bladder cancer	0.000249	0.000482	CcSEcCtD
Vardenafil—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000248	0.000481	CcSEcCtD
Vardenafil—Vomiting—Methotrexate—urinary bladder cancer	0.000248	0.000479	CcSEcCtD
Vardenafil—Rash—Methotrexate—urinary bladder cancer	0.000245	0.000475	CcSEcCtD
Vardenafil—Dermatitis—Methotrexate—urinary bladder cancer	0.000245	0.000475	CcSEcCtD
Vardenafil—Headache—Methotrexate—urinary bladder cancer	0.000244	0.000472	CcSEcCtD
Vardenafil—Asthenia—Doxorubicin—urinary bladder cancer	0.000242	0.000468	CcSEcCtD
Vardenafil—Dizziness—Epirubicin—urinary bladder cancer	0.000241	0.000466	CcSEcCtD
Vardenafil—Pruritus—Doxorubicin—urinary bladder cancer	0.000239	0.000462	CcSEcCtD
Vardenafil—Vomiting—Epirubicin—urinary bladder cancer	0.000232	0.000448	CcSEcCtD
Vardenafil—Nausea—Methotrexate—urinary bladder cancer	0.000231	0.000447	CcSEcCtD
Vardenafil—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000231	0.000446	CcSEcCtD
Vardenafil—Rash—Epirubicin—urinary bladder cancer	0.00023	0.000445	CcSEcCtD
Vardenafil—Dermatitis—Epirubicin—urinary bladder cancer	0.00023	0.000444	CcSEcCtD
Vardenafil—Headache—Epirubicin—urinary bladder cancer	0.000228	0.000442	CcSEcCtD
Vardenafil—Dizziness—Doxorubicin—urinary bladder cancer	0.000223	0.000431	CcSEcCtD
Vardenafil—Nausea—Epirubicin—urinary bladder cancer	0.000216	0.000419	CcSEcCtD
Vardenafil—Vomiting—Doxorubicin—urinary bladder cancer	0.000214	0.000415	CcSEcCtD
Vardenafil—Rash—Doxorubicin—urinary bladder cancer	0.000213	0.000411	CcSEcCtD
Vardenafil—Dermatitis—Doxorubicin—urinary bladder cancer	0.000212	0.000411	CcSEcCtD
Vardenafil—Headache—Doxorubicin—urinary bladder cancer	0.000211	0.000409	CcSEcCtD
Vardenafil—Nausea—Doxorubicin—urinary bladder cancer	0.0002	0.000387	CcSEcCtD
Vardenafil—PDE10A—Hemostasis—KRAS—urinary bladder cancer	0.000135	0.00143	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—S100B—urinary bladder cancer	0.000135	0.00143	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—HRAS—urinary bladder cancer	0.000135	0.00143	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—HRAS—urinary bladder cancer	0.000135	0.00143	CbGpPWpGaD
Vardenafil—PDE1B—Disease—RBX1—urinary bladder cancer	0.000134	0.00143	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—TP53—urinary bladder cancer	0.000134	0.00143	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—HRAS—urinary bladder cancer	0.000133	0.00142	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—IL2—urinary bladder cancer	0.000132	0.00141	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—HRAS—urinary bladder cancer	0.000132	0.00141	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—FGFR3—urinary bladder cancer	0.000132	0.0014	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—HRAS—urinary bladder cancer	0.000132	0.0014	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—SRC—urinary bladder cancer	0.00013	0.00139	CbGpPWpGaD
Vardenafil—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000129	0.00137	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—HRAS—urinary bladder cancer	0.000129	0.00137	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—RHOA—urinary bladder cancer	0.000128	0.00136	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000126	0.00134	CbGpPWpGaD
Vardenafil—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000125	0.00133	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—CREBBP—urinary bladder cancer	0.000125	0.00133	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NCOR1—urinary bladder cancer	0.000124	0.00132	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000123	0.00131	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—IGF1—urinary bladder cancer	0.000123	0.00131	CbGpPWpGaD
Vardenafil—PDE6G—Disease—CREBBP—urinary bladder cancer	0.000122	0.0013	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NCOR1—urinary bladder cancer	0.000121	0.00129	CbGpPWpGaD
Vardenafil—PDE1B—Disease—JAG1—urinary bladder cancer	0.00012	0.00128	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—IL2—urinary bladder cancer	0.00012	0.00128	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—TP53—urinary bladder cancer	0.00012	0.00128	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—TP53—urinary bladder cancer	0.00012	0.00128	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TERT—urinary bladder cancer	0.00012	0.00127	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—HRAS—urinary bladder cancer	0.000119	0.00127	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—IL2—urinary bladder cancer	0.000118	0.00125	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—HRAS—urinary bladder cancer	0.000115	0.00122	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—HRAS—urinary bladder cancer	0.000115	0.00122	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—EGFR—urinary bladder cancer	0.000114	0.00121	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	0.000114	0.00121	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—RHOA—urinary bladder cancer	0.000113	0.0012	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—CREBBP—urinary bladder cancer	0.000112	0.00119	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000112	0.00119	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IFNA2—urinary bladder cancer	0.000112	0.00119	CbGpPWpGaD
Vardenafil—PDE6G—Disease—RHOA—urinary bladder cancer	0.00011	0.00118	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—FGFR3—urinary bladder cancer	0.00011	0.00117	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TERT—urinary bladder cancer	0.000109	0.00117	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	0.000108	0.00115	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—NAT1—urinary bladder cancer	0.000108	0.00115	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—KRAS—urinary bladder cancer	0.000108	0.00115	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—IL2—urinary bladder cancer	0.000107	0.00114	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TERT—urinary bladder cancer	0.000107	0.00114	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—ESR1—urinary bladder cancer	0.000107	0.00114	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—S100B—urinary bladder cancer	0.000106	0.00112	CbGpPWpGaD
Vardenafil—PDE6G—Disease—ERBB2—urinary bladder cancer	0.000102	0.00109	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—FGFR3—urinary bladder cancer	0.0001	0.00107	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PTGS2—urinary bladder cancer	0.0001	0.00106	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	9.88e-05	0.00105	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—FGFR3—urinary bladder cancer	9.79e-05	0.00104	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—ESR1—urinary bladder cancer	9.76e-05	0.00104	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—ESR1—urinary bladder cancer	9.51e-05	0.00101	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—IL2—urinary bladder cancer	9.46e-05	0.00101	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—RBX1—urinary bladder cancer	9.41e-05	0.001	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—ERBB2—urinary bladder cancer	9.39e-05	0.001	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CREBBP—urinary bladder cancer	9.35e-05	0.000995	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—IGF1—urinary bladder cancer	9.23e-05	0.000983	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—EGFR—urinary bladder cancer	9.19e-05	0.000978	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—HRAS—urinary bladder cancer	9.17e-05	0.000975	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	8.89e-05	0.000946	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TSC1—urinary bladder cancer	8.85e-05	0.000942	CbGpPWpGaD
Vardenafil—PDE1B—Disease—NCOR1—urinary bladder cancer	8.76e-05	0.000932	CbGpPWpGaD
Vardenafil—PDE6G—Disease—CDKN1A—urinary bladder cancer	8.74e-05	0.00093	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PTEN—urinary bladder cancer	8.72e-05	0.000928	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—KRAS—urinary bladder cancer	8.68e-05	0.000924	CbGpPWpGaD
Vardenafil—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	8.64e-05	0.00092	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CREBBP—urinary bladder cancer	8.55e-05	0.00091	CbGpPWpGaD
Vardenafil—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.52e-05	0.000907	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—EP300—urinary bladder cancer	8.49e-05	0.000903	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—RHOA—urinary bladder cancer	8.46e-05	0.0009	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—IGF1—urinary bladder cancer	8.45e-05	0.000899	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—JAG1—urinary bladder cancer	8.43e-05	0.000897	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	8.4e-05	0.000894	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CREBBP—urinary bladder cancer	8.33e-05	0.000887	CbGpPWpGaD
Vardenafil—PDE6G—Disease—EP300—urinary bladder cancer	8.32e-05	0.000885	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—SRC—urinary bladder cancer	8.25e-05	0.000878	CbGpPWpGaD
Vardenafil—PDE1B—Disease—ERCC2—urinary bladder cancer	8.24e-05	0.000877	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—IGF1—urinary bladder cancer	8.23e-05	0.000876	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—EGFR—urinary bladder cancer	8.19e-05	0.000872	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	8.18e-05	0.000871	CbGpPWpGaD
Vardenafil—PDE6G—Disease—SRC—urinary bladder cancer	8.09e-05	0.000861	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—CDKN1A—urinary bladder cancer	8.03e-05	0.000854	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—PTEN—urinary bladder cancer	8.01e-05	0.000852	CbGpPWpGaD
Vardenafil—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	7.94e-05	0.000845	CbGpPWpGaD
Vardenafil—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.83e-05	0.000834	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—ERBB2—urinary bladder cancer	7.83e-05	0.000833	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MTHFR—urinary bladder cancer	7.74e-05	0.000824	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—RHOA—urinary bladder cancer	7.74e-05	0.000823	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—KRAS—urinary bladder cancer	7.74e-05	0.000823	CbGpPWpGaD
Vardenafil—PDE1B—Disease—TERT—urinary bladder cancer	7.72e-05	0.000822	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—FGFR3—urinary bladder cancer	7.67e-05	0.000817	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—EP300—urinary bladder cancer	7.64e-05	0.000813	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—RHOA—urinary bladder cancer	7.54e-05	0.000802	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—SRC—urinary bladder cancer	7.43e-05	0.000791	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CXCL8—urinary bladder cancer	7.43e-05	0.00079	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—HRAS—urinary bladder cancer	7.38e-05	0.000785	CbGpPWpGaD
Vardenafil—PDE6G—Disease—MYC—urinary bladder cancer	7.25e-05	0.000771	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—ERBB2—urinary bladder cancer	7.16e-05	0.000762	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—RHOA—urinary bladder cancer	7.12e-05	0.000758	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—IL2—urinary bladder cancer	7.1e-05	0.000755	CbGpPWpGaD
Vardenafil—PDE6G—Disease—EGFR—urinary bladder cancer	7.09e-05	0.000754	CbGpPWpGaD
Vardenafil—PDE1B—Disease—FGFR3—urinary bladder cancer	7.09e-05	0.000754	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—ERBB2—urinary bladder cancer	6.98e-05	0.000743	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CCND1—urinary bladder cancer	6.92e-05	0.000736	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—KRAS—urinary bladder cancer	6.83e-05	0.000727	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—S100B—urinary bladder cancer	6.82e-05	0.000726	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CXCL8—urinary bladder cancer	6.79e-05	0.000723	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MMP9—urinary bladder cancer	6.72e-05	0.000715	CbGpPWpGaD
Vardenafil—PDE6G—Disease—KRAS—urinary bladder cancer	6.7e-05	0.000713	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.69e-05	0.000712	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PTEN—urinary bladder cancer	6.68e-05	0.000711	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CXCL8—urinary bladder cancer	6.62e-05	0.000704	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—HRAS—urinary bladder cancer	6.58e-05	0.0007	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—TYMP—urinary bladder cancer	6.54e-05	0.000696	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CREBBP—urinary bladder cancer	6.53e-05	0.000695	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—EGFR—urinary bladder cancer	6.51e-05	0.000693	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—IL2—urinary bladder cancer	6.49e-05	0.000691	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CDH1—urinary bladder cancer	6.48e-05	0.00069	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—RHOA—urinary bladder cancer	6.47e-05	0.000688	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—EP300—urinary bladder cancer	6.37e-05	0.000678	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CCND1—urinary bladder cancer	6.33e-05	0.000673	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—IL2—urinary bladder cancer	6.33e-05	0.000673	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—CXCL8—urinary bladder cancer	6.25e-05	0.000665	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—SRC—urinary bladder cancer	6.19e-05	0.000659	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CCND1—urinary bladder cancer	6.17e-05	0.000656	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—KRAS—urinary bladder cancer	6.15e-05	0.000655	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MMP9—urinary bladder cancer	6.14e-05	0.000654	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NCOR1—urinary bladder cancer	6.14e-05	0.000653	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CDKN1A—urinary bladder cancer	6.12e-05	0.000651	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PTEN—urinary bladder cancer	6.11e-05	0.00065	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—TP53—urinary bladder cancer	6.07e-05	0.000646	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CREBBP—urinary bladder cancer	6.03e-05	0.000642	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MMP9—urinary bladder cancer	5.99e-05	0.000637	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—IL2—urinary bladder cancer	5.98e-05	0.000636	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CDKN1A—urinary bladder cancer	5.97e-05	0.000635	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PTEN—urinary bladder cancer	5.95e-05	0.000633	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—NAT2—urinary bladder cancer	5.92e-05	0.00063	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—EP300—urinary bladder cancer	5.82e-05	0.00062	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—HRAS—urinary bladder cancer	5.81e-05	0.000618	CbGpPWpGaD
Vardenafil—PDE6G—Disease—HRAS—urinary bladder cancer	5.69e-05	0.000606	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—CXCL8—urinary bladder cancer	5.68e-05	0.000604	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—EP300—urinary bladder cancer	5.68e-05	0.000604	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—SRC—urinary bladder cancer	5.66e-05	0.000603	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MYC—urinary bladder cancer	5.55e-05	0.000591	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—SRC—urinary bladder cancer	5.52e-05	0.000587	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—ERBB2—urinary bladder cancer	5.47e-05	0.000582	CbGpPWpGaD
Vardenafil—PDE1B—Disease—RHOA—urinary bladder cancer	5.46e-05	0.000581	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—EGFR—urinary bladder cancer	5.43e-05	0.000578	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—IL2—urinary bladder cancer	5.43e-05	0.000578	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TERT—urinary bladder cancer	5.41e-05	0.000575	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	5.29e-05	0.000563	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—HRAS—urinary bladder cancer	5.23e-05	0.000556	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—KRAS—urinary bladder cancer	5.13e-05	0.000546	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—RRM2—urinary bladder cancer	5.11e-05	0.000543	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MYC—urinary bladder cancer	5.08e-05	0.00054	CbGpPWpGaD
Vardenafil—PDE1B—Disease—ERBB2—urinary bladder cancer	5.05e-05	0.000538	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	5.02e-05	0.000534	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—NAT1—urinary bladder cancer	5.02e-05	0.000534	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—EGFR—urinary bladder cancer	4.96e-05	0.000528	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—FGFR3—urinary bladder cancer	4.96e-05	0.000528	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IL2—urinary bladder cancer	4.96e-05	0.000528	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MYC—urinary bladder cancer	4.95e-05	0.000526	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PTGS2—urinary bladder cancer	4.94e-05	0.000526	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—EGFR—urinary bladder cancer	4.84e-05	0.000515	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—ESR1—urinary bladder cancer	4.82e-05	0.000513	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—ENO2—urinary bladder cancer	4.73e-05	0.000503	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	4.73e-05	0.000503	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—KRAS—urinary bladder cancer	4.69e-05	0.000499	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CDKN1A—urinary bladder cancer	4.68e-05	0.000498	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PTEN—urinary bladder cancer	4.67e-05	0.000496	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.59e-05	0.000489	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	4.59e-05	0.000488	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—KRAS—urinary bladder cancer	4.57e-05	0.000486	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TP53—urinary bladder cancer	4.56e-05	0.000485	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—EP300—urinary bladder cancer	4.45e-05	0.000473	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—HRAS—urinary bladder cancer	4.36e-05	0.000464	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—SRC—urinary bladder cancer	4.33e-05	0.00046	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CDKN1A—urinary bladder cancer	4.32e-05	0.000459	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PTEN—urinary bladder cancer	4.31e-05	0.000458	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CREBBP—urinary bladder cancer	4.22e-05	0.000449	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IGF1—urinary bladder cancer	4.17e-05	0.000444	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TP53—urinary bladder cancer	4.17e-05	0.000444	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—EGFR—urinary bladder cancer	4.15e-05	0.000442	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.13e-05	0.00044	CbGpPWpGaD
Vardenafil—PDE1B—Disease—EP300—urinary bladder cancer	4.11e-05	0.000437	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TP53—urinary bladder cancer	4.06e-05	0.000432	CbGpPWpGaD
Vardenafil—PDE1B—Disease—SRC—urinary bladder cancer	3.99e-05	0.000425	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—HRAS—urinary bladder cancer	3.99e-05	0.000424	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—KRAS—urinary bladder cancer	3.92e-05	0.000417	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.9e-05	0.000415	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—HRAS—urinary bladder cancer	3.88e-05	0.000413	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—RHOA—urinary bladder cancer	3.82e-05	0.000407	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—NQO1—urinary bladder cancer	3.81e-05	0.000406	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.8e-05	0.000405	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—EGFR—urinary bladder cancer	3.79e-05	0.000404	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—KRAS—urinary bladder cancer	3.58e-05	0.000381	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MYC—urinary bladder cancer	3.58e-05	0.000381	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—ERBB2—urinary bladder cancer	3.54e-05	0.000376	CbGpPWpGaD
Vardenafil—PDE1B—Disease—EGFR—urinary bladder cancer	3.5e-05	0.000373	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CXCL8—urinary bladder cancer	3.35e-05	0.000357	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—HRAS—urinary bladder cancer	3.33e-05	0.000355	CbGpPWpGaD
Vardenafil—PDE1B—Disease—KRAS—urinary bladder cancer	3.31e-05	0.000352	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IL2—urinary bladder cancer	3.21e-05	0.000341	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	3.18e-05	0.000338	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CCND1—urinary bladder cancer	3.13e-05	0.000333	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HRAS—urinary bladder cancer	3.05e-05	0.000324	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.04e-05	0.000324	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MMP9—urinary bladder cancer	3.03e-05	0.000323	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CDKN1A—urinary bladder cancer	3.02e-05	0.000322	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PTEN—urinary bladder cancer	3.02e-05	0.000321	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—TYMS—urinary bladder cancer	2.96e-05	0.000315	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	2.92e-05	0.000311	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	2.92e-05	0.000311	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—EP300—urinary bladder cancer	2.88e-05	0.000306	CbGpPWpGaD
Vardenafil—PDE1B—Disease—HRAS—urinary bladder cancer	2.81e-05	0.000299	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.8e-05	0.000298	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SRC—urinary bladder cancer	2.8e-05	0.000298	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.75e-05	0.000293	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	2.75e-05	0.000292	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	2.58e-05	0.000275	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MYC—urinary bladder cancer	2.51e-05	0.000267	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—EGFR—urinary bladder cancer	2.45e-05	0.000261	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.37e-05	0.000253	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KRAS—urinary bladder cancer	2.32e-05	0.000246	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.2e-05	0.000234	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.2e-05	0.000234	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.13e-05	0.000227	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PPARG—urinary bladder cancer	2.09e-05	0.000223	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TP53—urinary bladder cancer	2.06e-05	0.000219	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	2.01e-05	0.000214	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—HRAS—urinary bladder cancer	1.97e-05	0.00021	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.77e-05	0.000189	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.65e-05	0.000175	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.48e-05	0.000157	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.44e-05	0.000153	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.37e-05	0.000146	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.37e-05	0.000146	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.36e-05	0.000145	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.36e-05	0.000145	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.3e-05	0.000138	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.28e-05	0.000136	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.2e-05	0.000128	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PPARG—urinary bladder cancer	9.73e-06	0.000104	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	9.35e-06	9.95e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.66e-06	8.15e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.68e-06	7.11e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.37e-06	6.78e-05	CbGpPWpGaD
